<DOC>
	<DOCNO>NCT00538824</DOCNO>
	<brief_summary>Study Objectives 1 . To evaluate efficacy combination dexamethasone ( Decadron® ) , thalidomide ( Thalomid® ) , lenalidomide ( Revlimid® ) therapy patient relapse refractory multiple myeloma ( MM ) fail prior treatment lenalidomide thalidomide use monotherapies . 2 . To evaluate safety combination lenalidomide , dexamethasone , thalidomide therapy patient relapse refractory multiple myeloma .</brief_summary>
	<brief_title>Phase II Study Dexamethasone , Thalidomide Lenalidomide Subjects With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>This phase II study treatment program patient relapse refractory multiple myeloma prior treatment thalidomide lenalidomide separate regimen use single agent combination corticosteroid . Up 45 patient enrol . Patients sign inform consent form RevAssist® S.T.E.P.S® patient agreement form fulfill eligibility criterion enrol . DexTR therapy : Cycles 1-4 - Dexamethasone ( 40mg ) give day 1-4 , 9-12 , 17-20 28-day cycle . - Thalidomide give 50mg daily day 1-7 , thereafter 100mg daily day 8-28 first 28-day cycle . Thalidomide give 100mg/daily day 1-28 subsequent cycle . - Lenalidomide give 25mg daily day 1-21 28 day cycle . - Prophylactic medication , medication thrombosis risk , give . After complete 4 cycle : - Patients demonstrate disease progression time take study . - Patients achieve resolution monoclonal gammopathy detect serum immunofixation achieve plateau disease ( change M-spike detected serum protein electrophoresis ) &gt; 2 cycle transition maintenance therapy . - Patients continue respond without achieve either plateau CR continue induction therapy plateau &gt; 2 cycle CR absence untoward toxicity . These patient transition maintenance therapy . Maintenance therapy : Maintenance therapy consist : - Dexamethasone 20mg weekly day 1 , 8 , 15 , 22 28 day cycle ) - Lenalidomide 25 mg/daily day 1 - 21 28 day cycle . 15mg/daily day 1-21 28 day cycle lenalidomide give patient creatinine clearance &lt; 40cc/min* - Patients finish induction therapy DexTR reduce dose lenalidomide start maintenance therapy dose lenalidomide end induction therapy . For patient creatinine clearance &lt; 40cc / minute , lenalidomide dose low last induction therapy dose 15mg daily day 1 - 21 28 day cycle . Serial clinic visit laboratory measurement perform monitor treatment response . Those patient demonstrate progression disease point DexTR therapy take study . At end every cycle ( may coincide day 1 new cycle ) , response toxicity evaluate . During cycle 1 , patient lab work do weekly ( CBC differential blood electrolyte ) . All patient remain study disease progression side effect become excessive . Patients achieve stable plateau maintenance therapy define may take study eligible proceed high dose chemotherapy autologous stem cell transplantation .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Subject must voluntarily sign understand write informed consent . Age &gt; 18 year time sign consent form . Histologically confirm SalmonDurie stage II III MM . Stage I MM patient eligible display poor prognostic factor ( ß2M ≥5.5 mg/L , plasma cell proliferation index ≥5 % , albumin less 3.0 , unfavorable cytogenetics ) . Relapsed refractory myeloma define Appendix II , table 1 , progression disease either prior therapy lack response currently use therapy . Prior treatment prior lenalidomide thalidomide single agent combination dexamethasone , combination . No antimyeloma therapy within 14 day prior initiation study treatment . Patients may receive adjuvant antiresorptive therapy ( i.e. , pamidronate zoledronic acid ) routine care . Measurable disease define &gt; 1.0 g/dL serum monoclonal protein , &gt; 0.1 g/dL serum free light chain , &gt; 0.2 g/24 hr urinary Mprotein excretion , and/or measurable plasmacytoma ( ) . Karnofsky performance status ≥70 % ( &gt; 60 % due bony involvement myeloma . All study participant must register mandatory RevAssist® S.T.E.P.S.® program , willing able comply requirement RevAssist® S.T.E.P.S.® program . Females childbearing potential ( FCBP ) † must negative serum urine pregnancy test sensitivity least 50 mIU/mL within 10 14 day prior within 24 hour prescribe lenalidomide thalidomide ( prescription must fill within 7 day ) must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 4 week start take lenalidomide . FCBP must also agree ongoing pregnancy test . Men must agree use latex condom sexual contact female child bear potential even successful vasectomy . Able take aspirin daily prophylactic anticoagulation ( patient intolerant ASA may use warfarin low molecular weight heparin ) . Life expectancy ≥ 3 month Subjects must meet follow laboratory parameter : Absolute neutrophil count ( ANC ) ≥1000 cells/mm3 ( 1.0 x 109/L ) Platelets count ≥ 75,000/mm3 ( 75 x 109/L ) Serum SGOT/AST &lt; 3.0 x upper limit normal ( ULN ) Serum SGPT/ALT &lt; 3.0 x upper limit normal ( ULN ) Serum creatinine &lt; 2.5 mg/dL ( 221 µmol/L ) Serum total bilirubin &lt; 2.0 mg/dL ( 34 µmol/L ) Patients nonsecretory MM ( measurable monoclonal protein , free light chain , and/or Mspike blood urine ) . Prior history malignancy ( except basal cell squamous cell carcinoma skin carcinoma situ cervix breast ) unless disease free ≥ 5 year . Myocardial infarction within 6 month prior enrollment , NYHA ( New York Hospital Association ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Pregnant lactating female ineligible . Given potential study drug trigger worsen HIV viremia incidence opportunistic infection inpatient infect HIV virus , HIV1 HIV2 positive patient exclude . The interaction HAART study drug determine . Active hepatitis B hepatitis C infection . Active viral bacterial infection coexist medical problem would significantly increase risk treatment program . Any coexist medical problem laboratory evaluation , treat physician 's principal investigator 's opinion , make patient unsuitable participate clinical trial . Known hypersensitivity dexamethasone , lenalidomide , thalidomide . History thromboembolic event within past 6 month prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>myeloma</keyword>
	<keyword>relapsed refractory multiple myeloma</keyword>
</DOC>